Stockscreener 앱 받기
0.1861
17.65%
-0.0399
Aditxt Inc 주식(ADTX)의 최신 뉴스
Aditx Therapeutics stock hits 52-week low at $0.31 - Investing.com
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Decrease in Short Interest - Defense World
Aditxt Advances ADI-100 Therapy to Human Trials - TipRanks
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Quantisnow
Evofem Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits - Quantisnow
Evofem Biosciences Announces Financial Results for the Third Qua - GuruFocus.com
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - Marketscreener.com
Aditxt extends merger agreement end date to January 2025 - Investing.com
Aditxt extends merger agreement end date to January 2025 By Investing.com - Investing.com UK
Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc. - The Manila Times
Evofem Secures Investor Support for Proposed Merger through Voti - GuruFocus.com
Aditxt Inc. (ADTX) Quarterly 10-Q Report - Quartz
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADTX stock plunges to 52-week low of $0.32 amid market challenges - Investing.com Canada
Evofem Cuts Q3 Operating Loss 31%, Acquires SOLOSEC Rights Despite Sales Dip | ADTX Stock News - StockTitan
Enviri Corp (NYSE: NVRI): Blank Check On Growth? - Stocks Register
Appili Therapeutics shareholders vote in favor of Aditxt transaction - TipRanks
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025 - The Manila Times
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Update - Defense World
Aditxt suspends equity financing amid acquisition strategy - Investing.com
Aditxt suspends equity financing amid acquisition strategy By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low, touches $0.42 - Investing.com India
ADTX stock plunges to 52-week low, touches $0.42 By Investing.com - Investing.com UK
Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition | ADTX Stock News - StockTitan
Appili Therapeutics Announces Results of Special Meeting of Shareholders - The Manila Times
Appili Shareholders Approve Acquisition by Aditxt - TipRanks
Appili Therapeutics Announces Results of Special Meeting of Shareholders - GlobeNewswire Inc.
Aditxt announces Evofem secures voting agreements with investors for merger - TipRanks
Evofem Biosciences Gains Support for Aditxt Merger - TipRanks
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Quantisnow
Evofem Secures Investor Support for Proposed Merger through Voting Agreements - StreetInsider.com
Evofem Secures Key Merger Support as Aditxt Completes $5M Investment Commitment | ADTX Stock News - StockTitan
Aditxt Discloses Information About Compliance with Nasdaq Listing Requirements in 8-K Filing** - Defense World
Aditxt, Inc. Focuses on Growth Amid Nasdaq Compliance - TipRanks
A Biotech Empire Rises in Inland Southern California - Site Selection Magazine
Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com Australia
ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan
Aditxt receives positive FDA feedback on ATI-1801 development - Investing.com India
Evofem Biosciences enters agreements amid merger plans - Investing.com
Evofem Biosciences Faces Merger and Credit Challenges - TipRanks
Evofem Biosciences enters agreements amid merger plans By Investing.com - Investing.com UK
ADTX stock plunges to 52-week low of $0.53 amid market challenges - Investing.com
Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - StockTitan
Appili Therapeutics’ FDA Alignment and Aditxt Acquisition - TipRanks
Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements - TipRanks
Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission - The Manila Times
Aditxt Enters Major Investment Agreement with Evofem - TipRanks
Aditxt appoints Sylvia Hermina to board By Investing.com - Investing.com Canada
Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives - Quantisnow
Aditxt appoints Sylvia Hermina to board - Investing.com
Aditxt, Inc. Appoints Sylvia Hermina to its Board of Directors - Marketscreener.com
2.88%
2.65%
자본화:
|
볼륨(24시간):